Nanotechnology Now - Press Release: Nanogen Announces Change in Board of Directors

Home > Press > Nanogen Announces Change in Board of Directors

Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced that Dr. William G. Gerber, a non-independent member of the company's board of directors, resigned from the board, effective as of May 1, 2007. His resignation restores compliance with NASDAQ Marketplace Rule 4350(c)(1), which requires a majority of members of the board of directors to be comprised of independent directors. The non-compliance resulted from the appointment of Dr. Heiner Dreismann, a non-independent director, to the company's board on October 31, 2006.

Nanogen Announces Change in Board of Directors

San Diego, CA | Posted on May 12th, 2007

The board of directors now is comprised of five (5) directors, three (3) of whom are independent within the meaning of the applicable NASDAQ listing standards.

On May 10, 2007, Nanogen, Inc. received a Nasdaq Staff Deficiency Letter indicating that the Company did not comply with the requirement for continued listing set forth in NASDAQ Marketplace Rule 4350(c)(1). As of the date of this press release, the company is again in full compliance with Nasdaq Marketplace Rule 4350(c)(1).

####

About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications.

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

For more information, please click here

Contacts:
Nanogen, Inc.
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
or
Suzanne Clancy, Corporate Communications, 858-410-4688

or
Porter Novelli Life Sciences
Kim Richards, Media & Investor Relations, 619-849-5377

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: